WO2003018010A1 - Agent prophylactique et/ou curatif pour les maladies induites par l'activite de l'arteriosclerose - Google Patents

Agent prophylactique et/ou curatif pour les maladies induites par l'activite de l'arteriosclerose Download PDF

Info

Publication number: WO2003018010A1
Authority: WO; WIPO (PCT)
Prior art keywords: preventive; arteriosclerotic activity; arteriosclerotic; activity; remedy
Prior art date: 2001-08-23

Application number

PCT/JP2002/008398

Other languages

English (en)

French (fr)

Inventor

Shinichi Ishii

Kazuyo Sasaki

Hiroaki Ueno

Original Assignee

Mitsubishi Pharma Corporation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-23

Filing date

2002-08-21

Publication date

2003-03-06

2002-08-21 Application filed by Mitsubishi Pharma Corporation filed Critical Mitsubishi Pharma Corporation

2002-08-21 Priority to JP2003522528A priority Critical patent/JPWO2003018010A1/ja

2002-08-21 Priority to EP02762812A priority patent/EP1419771A4/en

2002-08-21 Priority to US10/487,492 priority patent/US20040198774A1/en

2002-08-21 Priority to CA002457836A priority patent/CA2457836A1/en

2003-03-06 Publication of WO2003018010A1 publication Critical patent/WO2003018010A1/ja

Links

201000010099 disease Diseases 0.000 title abstract 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
230000000694 effects Effects 0.000 title abstract 3
230000003449 preventive effect Effects 0.000 title abstract 3
230000000246 remedial effect Effects 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 2
ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical group O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 abstract 1
239000004480 active ingredient Substances 0.000 abstract 1
230000001154 acute effect Effects 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
208000031225 myocardial ischemia Diseases 0.000 abstract 1
230000003389 potentiating effect Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
208000011580 syndromic disease Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PCT/JP2002/008398 2001-08-23 2002-08-21 Agent prophylactique et/ou curatif pour les maladies induites par l'activite de l'arteriosclerose WO2003018010A1 (fr)

Priority Applications (4)

Application Number	Priority Date	Filing Date	Title
JP2003522528A JPWO2003018010A1 (ja)	2001-08-23	2002-08-21	動脈硬化作用に基づく疾患の予防及び／または治療薬
EP02762812A EP1419771A4 (en)	2001-08-23	2002-08-21	AGENTS FOR THE PREVENTION AND / OR TREATMENT OF DISEASES THAT ARE ATTRIBUTED TO ARTERIOSCLEROTIC EFFECT
US10/487,492 US20040198774A1 (en)	2001-08-23	2002-08-21	Preventive and/or remedial agent for disease attributable to arteriosclerotic activity
CA002457836A CA2457836A1 (en)	2001-08-23	2002-08-21	Preventive and/or remedial agent for disease attributable to arteriosclerotic activity

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2001-252388		2001-08-23
JP2001252388		2001-08-23

Publications (1)

Publication Number	Publication Date
WO2003018010A1 true WO2003018010A1 (fr)	2003-03-06

Family

ID=19080872

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PCT/JP2002/008398 WO2003018010A1 (fr)	2001-08-23	2002-08-21	Agent prophylactique et/ou curatif pour les maladies induites par l'activite de l'arteriosclerose

Country Status (5)

Country	Link
US (1)	US20040198774A1 (ja)
EP (1)	EP1419771A4 (ja)
JP (1)	JPWO2003018010A1 (ja)
CA (1)	CA2457836A1 (ja)
WO (1)	WO2003018010A1 (ja)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2305352A1 (en)	2004-04-02	2011-04-06	Merck Sharp & Dohme Corp.	5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
WO2011069038A2 (en)	2009-12-03	2011-06-09	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2012027331A1 (en)	2010-08-27	2012-03-01	Ironwood Pharmaceuticals, Inc.	Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
WO2013082106A1 (en)	2011-12-02	2013-06-06	The General Hospital Corporation	Differentiation into brown adipocytes
WO2013138352A1 (en)	2012-03-15	2013-09-19	Synergy Pharmaceuticals Inc.	Formulations of guanylate cyclase c agonists and methods of use
WO2014151200A2 (en)	2013-03-15	2014-09-25	Synergy Pharmaceuticals Inc.	Compositions useful for the treatment of gastrointestinal disorders
WO2014151206A1 (en)	2013-03-15	2014-09-25	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase and their uses
EP2810951A2 (en)	2008-06-04	2014-12-10	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2014197720A2 (en)	2013-06-05	2014-12-11	Synergy Pharmaceuticals, Inc.	Ultra-pure agonists of guanylate cyclase c, method of making and using same
EP2998314A1 (en)	2007-06-04	2016-03-23	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839A1 (en)	2008-07-16	2017-11-08	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders

Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0604983A1 (en) *	1992-12-28	1994-07-06	Mitsubishi Chemical Corporation	Naphthalene derivatives
US6008237A (en) *	1997-12-19	1999-12-28	Merck & Co., Inc.	Arylthiazolidinedione derivatives
WO2000078312A1 (en) *	1999-06-18	2000-12-28	Merck & Co., Inc.	Arylthiazolidinedione and aryloxazolidinedione derivatives
WO2002013812A1 (en) *	2000-08-17	2002-02-21	Pershadsingh Harrihar A	Methods for treating inflammatory diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5968960A (en) *	1999-01-14	1999-10-19	The Regents Of The University Of California	Use of thiazolidinediones to ameliorate the adverse consequences of myocardial ischemia on myocardial function and metabolism
ES2211454T3 (es) *	1999-09-30	2004-07-16	Pfizer Products Inc.	Pirrolilamidas como inhibidores de la colageno fosforilasa.

2002
- 2002-08-21 EP EP02762812A patent/EP1419771A4/en not_active Withdrawn
- 2002-08-21 US US10/487,492 patent/US20040198774A1/en not_active Abandoned
- 2002-08-21 CA CA002457836A patent/CA2457836A1/en not_active Abandoned
- 2002-08-21 JP JP2003522528A patent/JPWO2003018010A1/ja not_active Withdrawn
- 2002-08-21 WO PCT/JP2002/008398 patent/WO2003018010A1/ja active Application Filing

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0604983A1 (en) *	1992-12-28	1994-07-06	Mitsubishi Chemical Corporation	Naphthalene derivatives
US6008237A (en) *	1997-12-19	1999-12-28	Merck & Co., Inc.	Arylthiazolidinedione derivatives
WO2000078312A1 (en) *	1999-06-18	2000-12-28	Merck & Co., Inc.	Arylthiazolidinedione and aryloxazolidinedione derivatives
WO2002013812A1 (en) *	2000-08-17	2002-02-21	Pershadsingh Harrihar A	Methods for treating inflammatory diseases

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JACKSON SIMON M. ET AL.: "Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction", ARTERIOSCLEROSIS, THROMBOSIS AND VASCULAR BIOLOGY, vol. 19, no. 9, 1999, pages 2094 - 2104, XP001004723 *
REGINATO MAURICIO J. ET AL.: "A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor gamma-activating properties", J. BIOL. CHEM., vol. 273, no. 49, 1998, pages 32679 - 32684, XP002960280 *
ZHU LINGYU ET AL.: "9-cis Retinoic acid induces monocyte chemoattractant protein-1 secretion in human monocytic THP-1 cells", ARTERIOSCLEROSIS, THROMBOSIS AND VASCULAR BIOLOGY, vol. 19, no. 9, 1999, pages 2105 - 2111, XP002960281 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2305352A1 (en)	2004-04-02	2011-04-06	Merck Sharp & Dohme Corp.	5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
EP2998314A1 (en)	2007-06-04	2016-03-23	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2810951A2 (en)	2008-06-04	2014-12-10	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839A1 (en)	2008-07-16	2017-11-08	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2011069038A2 (en)	2009-12-03	2011-06-09	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2923706A1 (en)	2009-12-03	2015-09-30	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia
WO2012027331A1 (en)	2010-08-27	2012-03-01	Ironwood Pharmaceuticals, Inc.	Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
WO2013082106A1 (en)	2011-12-02	2013-06-06	The General Hospital Corporation	Differentiation into brown adipocytes
WO2013138352A1 (en)	2012-03-15	2013-09-19	Synergy Pharmaceuticals Inc.	Formulations of guanylate cyclase c agonists and methods of use
EP3708179A1 (en)	2012-03-15	2020-09-16	Bausch Health Ireland Limited	Formulations of guanylate cyclase c agonists and methods of use
EP4309673A2 (en)	2012-03-15	2024-01-24	Bausch Health Ireland Limited	Formulations of guanylate cyclase c agonists and methods of use
WO2014151206A1 (en)	2013-03-15	2014-09-25	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase and their uses
WO2014151200A2 (en)	2013-03-15	2014-09-25	Synergy Pharmaceuticals Inc.	Compositions useful for the treatment of gastrointestinal disorders
WO2014197720A2 (en)	2013-06-05	2014-12-11	Synergy Pharmaceuticals, Inc.	Ultra-pure agonists of guanylate cyclase c, method of making and using same
EP4424697A2 (en)	2013-06-05	2024-09-04	Bausch Health Ireland Limited	Ultra-pure agonists of guanylate cyclase c, method of making and using same

Also Published As

Publication number	Publication date
EP1419771A1 (en)	2004-05-19
US20040198774A1 (en)	2004-10-07
EP1419771A4 (en)	2004-11-03
CA2457836A1 (en)	2003-03-06
JPWO2003018010A1 (ja)	2004-12-09

Legal Events

Date	Code	Title	Description
2003-03-06	AK	Designated states	Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
2003-03-06	AL	Designated countries for regional patents	Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
2003-04-03	DFPE	Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
2003-05-02	121	Ep: the epo has been informed by wipo that ep was designated in this application
2004-01-16	WWE	Wipo information: entry into national phase	Ref document number: 2003522528 Country of ref document: JP
2004-02-17	WWE	Wipo information: entry into national phase	Ref document number: 2457836 Country of ref document: CA
2004-02-18	WWE	Wipo information: entry into national phase	Ref document number: 2002762812 Country of ref document: EP
2004-02-23	WWE	Wipo information: entry into national phase	Ref document number: 10487492 Country of ref document: US
2004-05-19	WWP	Wipo information: published in national office	Ref document number: 2002762812 Country of ref document: EP

Publication	Publication Date	Title
DE60009929D1 (de)	2004-05-19	Glucopyranosyloxypyrazol-derivate, diese enthaltende arzneimittel und zwischenprodukte zu deren herstellung
NO20062713L (no)	2006-08-01	2,6 bisheteroaryl-4-aminopyrimidiner som adenosin reseptor antagonister
EP1400529A4 (en)	2007-12-19	GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL AND INTERMEDIARY USE THEREOF
MXPA04002035A (es)	2004-06-07	Derivados de 1, 8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados.
NO20060706L (no)	2006-02-14	Inhibitorer av serinproteaser, spesielt HCV NS3-NS4A-protease
EP1550662A4 (en)	2007-03-07	NEW ADENINE COMPOUND AND ITS USE
PL343771A1 (en)	2001-09-10	N-substituted aminotetralins as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders
CA2656716C (fr)	2014-10-14	Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
NO20062509L (no)	2006-06-26	Tetrazolderivater og fremgangsmater for behandling av stoffskifterelaterte forstyrrelser derav
WO2003018010A1 (fr)	2003-03-06	Agent prophylactique et/ou curatif pour les maladies induites par l'activite de l'arteriosclerose
MXPA03008134A (es)	2004-03-10	Compuesto de n-fenilarilsulfonamida, medicamento que contiene el compuesto como ingrediente activo, intermediario para el compuesto y procedimientos para su produccion.
CA2370244A1 (en)	2000-11-02	Piperidine derivatives
CA2336412A1 (en)	2000-01-13	Medicament for treatment of diabetes
WO2002060423A3 (en)	2003-04-10	Substituted carbostyril derivatives as 5-ht1a receptor subtype agonists
WO2004028455A3 (en)	2005-04-21	Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
MX2022015524A (es)	2023-03-22	Formas cristalinas del acido {2-[3-ciclohexil-3-(trans-4-propoxi-c iclohexil)-ureido]-tiazol-5-ilsulfanil}-acetico y uso de las mismas.
FI872930A0 (fi)	1987-07-02	Analogiamenetelmä ripulinvastaisten 4-(bentsoyyliamino)piperidiinibutaaniamidijohdannaisten valmistamiseksi
CA2373395A1 (en)	2002-08-28	Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors
DE60013560D1 (de)	2004-10-14	Malto-oligosaccharid-derivate und ihre anwendungen
JPH1087492A (ja)	1998-04-07	一酸化窒素産生阻害剤
MXPA01007705A (es)	2003-06-24	Derivado de benzamida y medicamento que lo contiene.
NO20070421L (no)	2007-01-23	Radiosensitiviserende middel
WO2000048447A3 (en)	2001-01-25	Composition for treatment of external secretion disorders except hypolacrimation
WO2004048381A3 (en)	2004-08-05	Pyrazoloazepine compounds as pharmaceutical agents
NO964497D0 (no)	1996-10-23	Middel for behandling av cor pulmonale